Vertex Pharma stock pre-market at EUR 450.78: plus 0.37 percent
Published on 10/05/2026 at 08:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharma stock is at EUR 450.78 pre-market on October 5, 2026, up 0.37 percent versus the Lang & Schwarz prior close of EUR 449.10. The quote was recorded at 8:15 a.m. CEST.
Pre-market trading
Lang & Schwarz showed a bid of EUR 449.10 and an ask of EUR 452.45 at 8:15 a.m. CEST on October 5, 2026. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.
Vertex reports inaxaplin study results
In a September 22, 2026 release, Vertex Pharmaceuticals Incorporated said its Phase 2b AMPLIFIED study evaluated a 45-milligram once-daily dose of inaxaplin in people with APOL1-mediated kidney disease. In the cohort with modest proteinuria, urine albumin to creatinine ratio fell 42.7 percent at Week 13 from baseline. In the cohort involving people with type 2 diabetes, the reduction was 17.3 percent.
The company also said it had completed enrollment in the Phase 2/3 AMPLITUDE trial. Vertex said it remained on track to share interim-analysis data in early 2027 once the relevant cohort reaches 48 weeks of treatment. The company stated that positive data could form the basis for potential accelerated approval in the United States. These statements are from the September 22, 2026 company release and are not a forecast of the stock price.
Prior close
The Lang & Schwarz prior close was EUR 449.10 on October 2, 2026, the previous Xetra trading day. The October 5 quote is a pre-market indication before the Xetra session begins.
